| ALNYLAM PHARMACE.DL-,0001 |
| USA |
| Gesundheit |
| US02043Q1076 / A0CBCK |
| DUL (Frankfurt) / ALNY (NASDAQ) |
| FRA:DUL, ETR:DUL, DUL:GR, NASDAQ:ALNY |
| Nasdaq100 |
| https://www.alnylam.com/ |
|
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference therapeutics. Alnylam Pharmaceuticals develops, manufactures, and commercializes medicines designed to silence disease-causing genes, with a primary emphasis on ..
>Volltext.. |
| 26759.91 Mio. EUR |
| 26478.78 Mio. EUR |
| 4288.57 Mio. EUR |
| 941.36 Mio. EUR |
| 721.27 Mio. EUR |
| 5.45 EUR |
| 2666.85 Mio. EUR |
| 1524.97 Mio. EUR |
| 790.81 Mio. EUR |
| 2.19 |
| 101.28% |
| - |
| - |
| - |
| - |
| ALNYLAM |
| 24.10.26 |